^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Title:

Resistance To Dasatinib In Philadelphia-Positive Leukemia Patients And The Presence Or The Selection Of Mutations At Residues 315 And 317 In The BCR-ABL Kinase Domain

Excerpt:
Thirteen patients had acquired resistance to dasatinib (patients #9–21 in Table 1 and Figure 1). Relapse occurred a median of 7 months (range, 3–15) after starting dasatinib. Mutation analysis performed before the onset of treatment showed that five of these patients had no evidence of nucleotide changes, while the remaining eight patients harbored various imatinib-resistant kinase domain mutations (G250E, Y253H, E255K, D276G, M351T, L387M; Table 1 and Figure 1).
DOI:
10.3324/haematol.10822